LIR Life Sciences Corp.

As of April 30, 2026, LIR Life Sciences Corp. carries a market capitalization of 15.77M, placing it among publicly traded companies globally. Its enterprise value stands at 15.17M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of April 30, 2026, LIR Life Sciences Corp. has 28.67M shares outstanding.

These figures are as of April 30, 2026.

As of April 30, 2026, LIR Life Sciences Corp. maintains a current ratio of 4.64, meaning it holds 4.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended April 30, 2026. Return on assets (ROA) is negative at -786.68, reflecting losses generated across the asset base.

Over the twelve months ended April 30, 2026, LIR Life Sciences Corp. generated - - in revenue and converted that into -3.77M in net income, yielding earnings per share of -0.13. EBITDA reached -3.39M, while operating income came in at -3.33M.

These figures are as of April 30, 2026. Total book value stands at 656,354.00, with working capital of 656,354.00 providing operational flexibility.

LIR Life Sciences Corp. produced -2.04M in operating cash flow over the twelve months ended April 30, 2026. After subtracting -105,000.00 in capital expenditures, free cash flow totaled -2.15M - equivalent to -0.08 per share.

These figures cover the twelve months ended April 30, 2026. Free cash flow yield is negative at -13.94: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

LIR Life Sciences Corp.'s most recent stock split took place on November 7, 2025 with a 3:2 split ratio.

As of April 30, 2026, LIR Life Sciences Corp. has an Altman Z-Score of 32.97, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.